Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok...

Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala
Lumpur, Bangkok and Manila

Move strengthens Kendle's position as a global clinical development partner to
the biopharmaceutical industry

CINCINNATI, June 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading,
global full-service clinical research organization, today announced the
opening of offices in Kuala Lumpur, Malaysia; Bangkok, Thailand; and Manila,
Philippines. The new operations provide Kendle's global biopharmaceutical
customers with access to additional patient populations while strengthening
the Company's position as a global clinical development partner. Kendle has
been active in the Asia/Pacific region since 1998 and currently operates
offices in Beijing, Hong Kong and Shanghai, China; New Delhi and Ahmedabad,
India; Singapore; and Sydney and Melbourne, Australia.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Kendle is one of the few truly global providers offering comprehensive Phase
I-IV solutions to meet the needs of the world's biopharmaceutical industry,"
said Candace Kendle, PharmD, Chairman and CEO. "Our expanded presence in the
Asia/Pacific region enhances opportunities for patient access, creates
efficiencies in the clinical development process and overall strengthens
Kendle's ability to foster global strategic alliances with the leading
companies in the biopharmaceutical industry."

Kendle's expansion in Asia/Pacific reflects the growing importance of the
region to the global clinical research market. Recent research by the Tufts
Center for the Study of Drug Development indicates that within the next three
years, as much as 65 percent of all FDA-regulated clinical trials will be
conducted outside the United States, with a significant number of these
studies moving to Asia. Clinical research organizations with a sound
understanding of the Asian marketplace will have a sizeable advantage.

"With more than half of the world's population, Asia offers an abundance of
patients in nearly every therapeutic area," added Dr. Ross Horsburgh, Vice
President, Global Clinical Development - Asia/Pacific. "Furthermore,
governments have highlighted biopharmaceutical development as a key pillar to
their economies, resulting in much more favorable environments for global
clinical development work."

The new Kendle offices are located at:

Kendle Sdn Bhd
Level 16, 1 Sentral
Jalan Stesen Sentral 5
KL Sentral, 50470
Kuala Lumpur
Malaysia

Kendle C.R.O. (Thailand) Co., Ltd.
23/F M Thai Tower, All Seasons Place
87 Wireless Road
Lumpini, Phatumwan
Bangkok 10330 Thailand

Kendle CRO Philippines, Inc.
18th Floor Philamlife Tower
8767 Paseo de Roxas
Makati City 1226, Philippines

About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research
organization providing the full range of early- to late-stage clinical
development services for the world's biopharmaceutical industry. Our focus is
on innovative solutions that reduce cycle times for our customers and
accelerate the delivery of life-enhancing drugs to market for the benefit of
patients worldwide. As one of the fastest-growing global providers of Phase
I-IV services, we offer experience spanning more than 100 countries, along
with industry-leading patient access and retention capabilities and broad
therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's
Web site at www.kendle.com.

Certain statements contained in this press release may be deemed to be
forward-looking statements under federal securities laws, and Kendle intends
that such forward-looking statements be subject to the safe-harbor created
thereby. Such forward-looking statements include, but are not limited to
Kendle's existing and planned growth and market penetration in the Asia
Pacific region, including India. Kendle cautions that these statements are
qualified by important factors that could cause actual results to differ
materially from those reflected by the forward-looking statements contained
herein. Such factors include (a) fluctuation in the exchange rate of the U.S.
dollar to other currencies; (b) the ability to set up and sustain growth
entities in the above described regions; (c) changes in the markets for the
company's service offerings; (d) changes in the market for customers'
products; and (e) other risks as detailed from time to time in Kendle's SEC
reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form
8-K, and Annual Reports on Form 10-K.

SOURCE Kendle International Inc.

Investors, Michael Lawson, +1-513-763-1992, Media, Lori Dorer,
+1-513-345-1685, both of Kendle International Inc.